Nontypable
The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae ( H. influenzae ) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae . Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection with nontypable Haemophilus influenzae and methods for the treatment or prevention of an infection with nontypable Haemophilus influenzae.
1. A purified and isolated antigen consisting of: (i) an isolated polypeptide of SEQ ID NO: 656 or a polypeptide that has least 96% sequence identity to the amino acid sequence set forth as SEQ ID NO: 656, where in the antigen is 539 amino acids in length; or (ii) an immunogenic fragment of SEQ ID NO: 191, wherein the fragment consisting of amino acids 1-33, 60-66, 68-81, 86-100, 102-111, 126-137, 140-150, 163-171, 189-210, 214-221, 227-234, 263-269, 280-287, 295-302, 309-314, 318-328, 336-343, 350-356, 363-369, 381-390, 408-432, 449-461, 463-498, 506-530, 532-544, 65-402, 405-565, 66-151 or 192-261 of SEQ ID NO 191.
2. A fusion protein comprising the antigen according to claim 1 , and a heterologous amino acid sequence.
3. The fusion protein according to claim 2 , wherein the heterologous amino acid sequence is a marker protein.
4. The fusion protein according to claim 2 , wherein the heterologous amino acid sequence is a secretory sequence, a sequence employed for purification, or a proprotein sequence.
5. A fusion protein comprising 2 or more fragments set forth in claim 1 , wherein the fusion protein is less than 565 amino acids in length.
6. An immunogenic composition, comprising a purified and isolated antigen, or an immunogenic fragment thereof, as set forth in claim 1 , or a fusion protein as set forth in claim 2 .
7. A method for eliciting an immune response in an animal or human, comprising administering to said animal or human an amount of the immunogenic composition of claim 6 effective to elicit an immune response.
8. A method for eliciting an immune response in an animal or human, comprising administering to said animal or human an amount of the antigen, or immunogenic fragment thereof, as set forth in claim 1 , or a fusion protein as set forth in claim 2 , effective to elicit an immune response.